Potentiation of cytotoxicity by combination of imatinib and chlorimipramine in glioma

Abstract

Abstract. Rat C6 glioma is a chemo-resistant experimental brain tumor that is difficult to treat with various drug combinations. Previous studies suggested that imatinib mesylate (Gleevec) is effective in pre-clinical trials for glioblastoma. Also, chlorimipramine (Anafranil) is an anti-depressant drug in use in the clinic and shown to have anti-neoplastic activity. We hypothesized that treatment of resistant C6 glioma with combination of imatinib and chlorimipramine may potentiate cytotoxicity and reverse resistance. C6 glioma was examined both as monolayer and as spheroid cultures. Several experimental designs were examined all of which showed synergistic activity albeit at different time kinetics. Combination treatment resulted in inhibition of cell growth and enhanced cell death as determined by dye exclusion. Further, the combination treatment resulted in significant induction of apoptosis as determined by Annexin V-FITC and PI. Also, there was inhibition of DNA synthesis and cAMP. Altogether, these findings supported the antiproliferative and cytotoxic effects of the combination treatment. Morphological studies were also performed using transmission and scanning electron microscopy. Significant synergistic apoptosis was detected by the combination treatment in both the monolayers and spheroid cultures. There was also a synergistic effect in autophagy by the combination. Several altered morphological features were noted by both the individual compound and enhanced by the combination treatment. The present findings support our hypothesis and demonstrate the potentiation of cytotoxicity by the com-bination of imatinib and chlorimipramine in C6 glioma. Further, the findings suggest the potential clinical application of the combination in the treatment of drugresistant glioma.

Comparing progression molecular mechanisms between lung adenocarcinoma and lung squamous cell carcinoma based on genetic and epigenetic networks: big data mining and genome-wide systems identification

“…Clomipramine, an antineoplastic agent, can lead to cancer cell apoptosis. It has been shown that chlorimipramine has positive effects against human leukaemia cells, and human renal cancer cells [203, 204]. Besides, it has been also reported that rolipram can result in a decreased proliferation and an increased apoptosis in malignant glioma cells [205].…”

Antidepressants with anti‐tumor potential in treating glioblastoma: A narrative review

“…In DK‐MG cells, an established GBM (grade IV) cell line p23–27 derived from a 67‐year‐old female, clomipramine was shown to induce a robust apoptotic effect up to 51%, whereas the positive control, as staurosporine, led to more apoptosis (71% at 6 h) [22]. Combinational therapy of clomipramine and imatinib in C6 cell line represented a synergistic effect in suppressing cell proliferation [23]. In addition, clomipramine and imatinib showed a synergistic effect on both autophagy and apoptosis in the monolayers and spheroid cultures.…”

Emerging therapeutic potential of anti-psychotic drugs in the management of human glioma: A comprehensive review

“…A combination treatment study with clomipramine and imatinib (both at 10 μM for 96 h) in C6 cells displayed synergistic inhibition of cell proliferation, viability, and inhibition of DNA synthesis with an enhanced annexin-V-positive cell percentage at 24 h (35.49% increased to 61.95%) and 96 h (80.49% increased to 86.52%) [51]. Furthermore, the addition of clomipramine significantly reduced cAMP levels to 30.40 and 5.19 pmol/ml (at 24 h and 96 h, respectively) as compared with exposure to imatinib alone (61.61 and 37.68 pmol/ml at 24 h and 96 h, respectively).…”